Trial
NCT02854059
IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hansa Biopharma AB
Collaborators
University College London Hospitals
Condition
Purpura, Thrombotic Thrombocytopenic
Intervention
IdeS (0.25 mg/kg)
Why stopped
Sponsor review of initial results demonstrates a non-favourable risk benefit
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-13